LeMaitre Vascular (LMAT) Stock Forecast & Price Target

$94.04 +1.41 (+1.52%)

(As of 05:45 PM ET)

LeMaitre Vascular - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 9 Analyst Ratings

Sell
0

Hold
2

Buy
7

Based on 9 Wall Street analysts who have issued ratings for LeMaitre Vascular in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 9 analysts, 2 have given a hold rating, 6 have given a buy rating, and 1 has given a strong buy rating for LMAT.

Consensus Price Target

$94.57
0.57% Upside

According to the 9 analysts' twelve-month price targets for LeMaitre Vascular, the average price target is $94.57. The highest price target for LMAT is $105.00, while the lowest price target for LMAT is $75.00. The average price target represents a forecasted upside of 0.57% from the current price of $94.04.

Get the Latest News and Ratings for LMAT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for LeMaitre Vascular and its competitors.

LMAT Analyst Ratings Over Time

Type	Current Forecast 12/27/23 to 12/26/24	1 Month Ago 11/27/23 to 11/26/24	3 Months Ago 9/28/23 to 9/27/24	1 Year Ago 12/27/22 to 12/27/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)	4 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$94.57	$94.57	$94.40	$67.60
Forecasted Upside	0.57% Upside	-10.30% Downside	2.93% Upside	17.22% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Buy	Moderate Buy

Man Who Called Nvidia Says: “Your Retirement Is Inside This Building.” (Ad)

In 2016, Jeff Brown called Nvidia at a split-adjusted 66 cents. The company just became the world's third $3 trillion company... And the stock is up massively since Jeff's recommendation.

Now, Jeff has found five under-the-radar stocks which could power your retirement.

LMAT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

LMAT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

LeMaitre Vascular Stock vs. The Competition

Type	LeMaitre Vascular	Medical Companies	S&P 500
Consensus Rating Score	2.89	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	1.58% Upside	25,941.43% Upside	13.25% Upside
News Sentiment Rating	Positive News See Recent LMAT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/1/2024	Oppenheimer 3 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$90.00 ➝ $93.00	-6.96%
11/1/2024	Barrington Research 4 of 5 stars		Boost Target	Outperform ➝ Outperform	$92.00 ➝ $93.00	-7.01%
10/15/2024	Cantor Fitzgerald 4 of 5 stars	R. Osborn Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$96.00	+4.19%
8/20/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Outperform ➝ Market Outperform	$77.00 ➝ $100.00	+16.92%
8/2/2024	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$85.00 ➝ $105.00	+20.73%
5/31/2024	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Wittes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/31/2024	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$100.00	+26.95%
4/26/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$59.00 ➝ $75.00	+19.07%
2/6/2024	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Sector Weight
8/3/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$63.00 ➝ $67.00	+3.55%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:10 PM ET.

LMAT Forecast - Frequently Asked Questions

: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for LeMaitre Vascular is $94.57, with a high forecast of $105.00 and a low forecast of $75.00.
: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LeMaitre Vascular in the last twelve months. There are currently 2 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LMAT shares.
: According to analysts, LeMaitre Vascular's stock has a predicted upside of 0.57% based on their 12-month stock forecasts.
: LeMaitre Vascular has been rated by research analysts at Barrington Research, Cantor Fitzgerald, and Oppenheimer in the past 90 days.
: Analysts like LeMaitre Vascular more than other "medical" companies. The consensus rating score for LeMaitre Vascular is 2.89 while the average consensus rating score for "medical" companies is 2.81. Learn more on how LMAT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment (Ad)

This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.

Click here for the ticker >>>

This page (NASDAQ:LMAT) was last updated on 12/26/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LeMaitre Vascular (LMAT) Stock Forecast & Price Target